Ajax loader
By using our website, you agree to our use of cookies as described in Cookie Policy.

Can't find what you're looking for?

 

Be sure to Sign in to see all available content.

 

If you don't have an account, Register here.

Search results for:

BIOGEN-ALZHEIMERS/
RTXD2W0Y
February 21, 2020
Charles Flagg, who took part in an early stage trial of Biogen's drug Aducanumab following his diagnosis...
JAMESTOWN, UNITED STATES
Charles Flagg sit in his home following his diagnosis with Alzheimer's disease in Jamestown
Charles Flagg, who took part in an early stage trial of Biogen's drug Aducanumab following his diagnosis with Alzheimer's disease, sits in his home in Jamestown, Rhode Island, U.S., February 21, 2020. On June 7, 2021 the U.S. Food and Drug Administration (FDA) approved Aduhelm (aducanumab) as the first treatment to target a likely underlying cause of Alzheimer's disease - sticky deposits of a protein called amyloid beta. Picture taken February 21, 2020. REUTERS/Brian Snyder
Sort by
Display
Items per page
Page
of 1